These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 31377953

  • 1. Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis.
    García-Rodríguez JF, Valcarce-Pardeiro N, Álvarez-Díaz H, Mariño-Callejo A.
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2121-2126. PubMed ID: 31377953
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE.
    Am J Respir Crit Care Med; 2006 Apr 15; 173(8):922-6. PubMed ID: 16474028
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O, Haegi V, Villiger B, Bohn W, Baumann HR, Zäch R.
    Schweiz Med Wochenschr; 1989 Mar 11; 119(10):299-305. PubMed ID: 2652281
    [Abstract] [Full Text] [Related]

  • 7. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
    Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC, Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators.
    Ann Intern Med; 2002 Oct 15; 137(8):640-7. PubMed ID: 12379063
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2003 Oct 15; 78(10):611-7. PubMed ID: 14621568
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
    Duarte R, Carvalho A, Correia A.
    Public Health; 2012 Sep 15; 126(9):760-2. PubMed ID: 22633080
    [No Abstract] [Full Text] [Related]

  • 14. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr 15; 143(4 Pt 1):707-12. PubMed ID: 1901200
    [Abstract] [Full Text] [Related]

  • 15. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M.
    Kekkaku; 2001 Jan 15; 76(1):33-43. PubMed ID: 11211781
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R, Heilig CM, Tapy JM, Bozeman L, Kyle RP, Hamilton CD, Bock N, Narita M, Wing D, Hershfield E, Goldberg SV, Tuberculosis Trials Consortium.
    Int J Tuberc Lung Dis; 2014 May 15; 18(5):571-80. PubMed ID: 24903795
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.
    Namasivayam S, Maiga M, Yuan W, Thovarai V, Costa DL, Mittereder LR, Wipperman MF, Glickman MS, Dzutsev A, Trinchieri G, Sher A.
    Microbiome; 2017 Jul 07; 5(1):71. PubMed ID: 28683818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.